•
Mar 31, 2024

Natera Q1 2024 Earnings Report

Driven by robust volume, revenue and margin growth, the company achieved cash flow breakeven earlier than expected.

Key Takeaways

Natera reported a strong start to the year with significant growth in volume, revenue, and margin, achieving cash flow breakeven ahead of schedule. Total revenues increased by 52.1% to $367.7 million, driven by a 53.4% increase in product revenues. The company processed approximately 735,800 tests and reported a net loss of $67.6 million, or ($0.56) per diluted share.

Total revenues increased by 52.1% to $367.7 million compared to Q1 2023.

Product revenues grew by 53.4% to $364.7 million driven by volume and average selling price improvements.

Approximately 735,800 tests were processed, including 718,700 tests accessioned in the laboratory.

Net loss for the quarter was $67.6 million, or ($0.56) per diluted share, compared to a net loss of $136.9 million in Q1 2023.

Total Revenue
$368M
Previous year: $242M
+52.1%
EPS
-$0.56
Previous year: -$1.23
-54.5%
Tests Processed
735.8K
Previous year: 626.2K
+17.5%
Tests Accessioned
718.7K
Previous year: 607.7K
+18.3%
Total Tests Reported
679.4K
Previous year: 583.4K
+16.5%
Gross Profit
$209M
Previous year: $93.6M
+122.9%
Cash and Equivalents
$883M
Previous year: $812M
+8.7%
Free Cash Flow
$6.69M
Previous year: -$92.5M
-107.2%
Total Assets
$1.47B
Previous year: $1.32B
+11.3%

Natera

Natera

Natera Revenue by Segment

Forward Guidance

Natera anticipates 2024 total revenue of $1.42 billion to $1.45 billion; 2024 gross margin to be approximately 53% to 55% of revenues; selling, general and administrative costs to be approximately $700 million to $750 million; research and development costs to be $350 million to $375 million, and net cash inflow (consumption) to be ($25) million to $25 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income